We're thrilled to announce the Anaqua and PatSnap partnership. Together, we'll combine our cutting-edge technologies and capabilities to enable best practices in the management of Intellectual Property for our Life Science clients.

Anaqua AQX® Pharma helps clients manage the business processes of Pharmaceutical IP Management, while Synapse enables drug discovery through external and competitor AI-powered drug discovery processes. Our integrated solution powers end-to-end Product IP Management including stage gate-driven reviews of changes in the external considerations and environment.

Through this partnership, AQX customers get unlimited access to PatSnap's life sciences innovation intelligence solution, Synapse. Combined, these platforms allow users to uncover associations between diseases, target companies, and drugs while improving R&D and accelerating time to market.

AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
PaxlovidPD-1Pfizer Inc.
76
k
Drugs & Biologics
44
k
Targets
909
k
Organizations
851
k
Clinical Trials
63,524
k
Literatures
15,842
k
Patents
Check out our latest report
View all reports →
Global Drug R&D Express (Aug. 2023)

Global Drug R&D Express (Aug. 2023)

Based on data from the Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts:1.First Approved Drugs in July; 2. New Drug Analysis; 3.Global Drugs under Expedited Review Pathway in July; 4. Analysis of Selected ERP Drugs

Read →
Global Drug R&D Express (Jul. 2023)

Global Drug R&D Express (Jul. 2023)

Based on data from the PatSnap Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts:1.First Approved Drugs in July; 2. New Drug Analysis; 3. Global Drugs under Expedited Review Pathway in July; 4. Analysis of Selected ERP Drugs

Read →
Global Drug R&D Express (Jun. 2023)

Global Drug R&D Express (Jun. 2023)

Based on the latest data from PatSnap Synapse, we has released the "Global Drug R&D Express (May 2023)". The report includes a total of 75 drugs consisting of: ◉ 14 drugs first approved globally: 7Small molecule drug (SMD), 1 Monoclonal antibody(mAb), 1 Enzyme, 1 CAR-T, 1 Fc fragment, 1 Cell therapy, 1 Adeno-associated virus gene therapy 1 traditional Chinese medicine.◉ 58 drugs under Expedited Review pathways worldwide: 32 Orphan Drug designation, 12 Fast Track designation, 9 Priority review, 4 Breakthrough Therapy designation, 2 Accelerated Approval, 1 Qualified Infectious Disease Product, 1 PRIME. The report also highlights 5 first approved drugs and 6 Expedited Review Pathway drugs providing a detailed interpretation of the drugs from multiple aspects such as basic information, R&D status, technical barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →
Latest news
View all news →
news cover
U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
22 Sep 2023
news cover
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
22 Sep 2023
news cover
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
22 Sep 2023
news cover
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
22 Sep 2023
Who We Serve
View our solutions →
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.